Page last updated: 2024-11-04

risedronic acid and Chronic Disease

risedronic acid has been researched along with Chronic Disease in 8 studies

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"Alendronate was the most frequently implicated (six cases) and risedronate (five cases)."1.36[Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010)
"We studied the bone resorption state in GC-treated CKD patients and the effects of bisphosphonate on S-NTX."1.33Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. ( Fujii, N; Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Moriyama, T; Nagasawa, Y; Okada, N, 2006)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abdou, WM1
Ganoub, NA1
Geronikaki, A1
Sabry, E1
Kunchur, R1
Need, A1
Hughes, T1
Goss, A1
Barrier, A1
Lescaille, G1
Rigolet, A1
Descroix, V1
Goudot, P1
Ruhin, B1
Yurci, A1
Kalkan, AO1
Ozbakir, O1
Karaman, A1
Torun, E1
Kula, M1
Baskol, M1
Gursoy, S1
Yucesoy, M1
Bayram, F1
Konrat, C1
Boutron, I1
Trinquart, L1
Auleley, GR1
Ricordeau, P1
Ravaud, P1
Wright, SA1
Millar, AM1
Coward, SM1
Finch, MB1
Hamano, T2
Fujii, N2
Nagasawa, Y2
Isaka, Y2
Moriyama, T2
Okada, N1
Imai, E2
Horio, M2
Ito, T2
Mikami, S1
Hori, M1

Trials

3 trials available for risedronic acid and Chronic Disease

ArticleYear
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:6

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Co

2009
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:12

    Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agen

2011
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:6

    Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Drug Therapy, Combination

2007

Other Studies

5 other studies available for risedronic acid and Chronic Disease

ArticleYear
Synthesis, properties, and perspectives of gem-diphosphono substituted-thiazoles.
    European journal of medicinal chemistry, 2008, Volume: 43, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Bone Resorption;

2008
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
    Revue de stomatologie et de chirurgie maxillo-faciale, 2010, Volume: 111, Issue:4

    Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu

2010
Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.
    PloS one, 2012, Volume: 7, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chronic Disease; Etidronic Acid; Fluorobenzenes; France

2012
Chronic diffuse sclerosing osteomyelitis treated with risedronate.
    The Journal of rheumatology, 2005, Volume: 32, Issue:7

    Topics: Adult; Calcium Channel Blockers; Chronic Disease; Etidronic Acid; Female; Humans; Osteomyelitis; Pai

2005
Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
    Bone, 2006, Volume: 39, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Bone Density; Bone Density

2006